grey glp-1 peptide analogs for targeting pancreatic beta cells How GLP 1 Medications May

Scientific Reports, 7 (1), 111

For instance, semaglutide has been approved and is being researched for indications including obesity, T2DM, reducing cardiovascular risk, chronic kidney disease, NAFLD, and AD, indicating that the development of new indications could provide new growth opportunities for GLP-1 drugs

For diabetes patients, A1c reductions of approximately 1.0-1.5 percentage points are common with GLP-1 receptor agonists, while tirzepatide has shown reductions of up to 2.0-2.3 percentage points in clinical trials

J., Philippe, J., Mojsov, S., Chick, W

The GLP-1 receptor (GLP-1R) is expressed in pancreatic beta cells, the central nervous system, and the gastrointestinal tract

Recent advances in incretin-based pharmacotherapies for the treatment of obesity and diabetes